![Don Soland](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Don Soland
Keine laufenden Positionen mehr
Vermögen: 953 928 $ am 31.05.2026
Profil
Daniel B. Soland was Director-Worldwide Marketing Operations & VP at Corixa Corp.
from 1993 to 2002.
Served as President & Chief Executive Officer at Epigenesis Pharmaceuticals LLC from 2002 to 2005.
Held the position of President at Seqirus Vaccines Ltd. from 2005 to 2006.
Was President-Chiron Vaccines at Chiron Corp.
from 2005 to 2006.
Chief Operating Officer & Senior Vice President at Viropharma, Inc. from 2008 to 2014.
Chief Operating Officer & Senior Vice President at Shire ViroPharma, Inc. from 2008 to 2014.
Chief Executive Officer & Executive Director at uniQure NV in 2016.
Independent Director at ACADIA Pharmaceuticals, Inc. from 2015 to 2025.
Independent Director at DBV Technologies SA from 2015 to 2025.
Non-Executive Director at Oxford Biomedica Plc from 2015 to 2016.
Independent Director at KalVista Pharmaceuticals, Inc. from 2019 to 2022.
Chief Operating Officer & Senior Vice President at Idera Pharmaceuticals, Inc. from 2020 to 2022.
Director at Tarsa Therapeutics, Inc. Education includes undergraduate studies at the University of Iowa.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 29.05.2025 | 44.041 ( 0,03 % ) | 953 928 $ | 31.05.2026 |
Ehemalige bekannte Positionen von Don Soland
| Unternehmen | Position | Ende |
|---|---|---|
| ACADIA PHARMACEUTICALS INC. | Direktor/Vorstandsmitglied | 30.10.2025 |
| DBV TECHNOLOGIES | Direktor/Vorstandsmitglied | 18.09.2025 |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Geschäftsführer | 28.09.2022 |
| KALVISTA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 26.05.2022 |
| UNIQURE N.V. | Vorstandsvorsitzender | 22.09.2016 |
Ausbildung von Don Soland
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
59
Beziehungen ersten Grades
14
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 14 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Health Technology |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Shire ViroPharma, Inc.
 Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs | Health Technology |
Corixa Corp.
 Corixa Corp. BiotechnologyHealth Technology Develops and manufactures oncology and immunology products | Health Technology |
ACADIA Pharmaceuticals, Inc.
 ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
Seqirus Vaccines Ltd.
 Seqirus Vaccines Ltd. BiotechnologyHealth Technology Manufactures vaccines | Health Technology |
Oxford Biomedica Plc
 Oxford Biomedica Plc BiotechnologyHealth Technology Operates as a contract development and manufacturing organization which provides viral vectors to pharmaceutical and biotechnology clients in cell and gene therapy fields | Health Technology |
University of Iowa
 University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Epigenesis Pharmaceuticals LLC
 Epigenesis Pharmaceuticals LLC Pharmaceuticals: OtherHealth Technology Develops inhaled respiratory medicines | Health Technology |
DBV Technologies SA
 DBV Technologies SA Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that focuses on changing the field of immunotherapy | Health Technology |
Tarsa Therapeutics, Inc.
 Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel oral treatment for post-menopausal osteoporosis | Health Technology |
uniQure NV
 uniQure NV BiotechnologyHealth Technology Engages in the discovery, development and commercialization of gene therapies products | Health Technology |
KalVista Pharmaceuticals, Inc.
 KalVista Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets small molecule protease inhibitors for diseases | Health Technology |
Viropharma, Inc. |
